Pre-existing cell subpopulations in primary prostate cancer tumors display surface fingerprints of docetaxel-resistant cells.
Stanislav DrápelaBarbora KvokačkováEva SlabákováAnna KotrbováKristína GömöryováRadek FedrDaniela KurfürstováMartin EliášVladimír ŠtudentFrederika LenčéšováGanji Sri RanjaniVendula PospíchalováVítězslav BryjaWytske M van WeerdenMartin PuhrZoran CuligJan BouchalKarel SoučekPublished in: Cellular oncology (Dordrecht, Netherlands) (2024)
In summary, we demonstrate that the identified 6-molecule surface fingerprint associated with docetaxel resistance pre-exists in a subpopulation of primary PCa tumors before docetaxel treatment. Thus, this fingerprint warrants further validation as a promising predictive tool for docetaxel resistance in PCa patients prior to therapy initiation.
Keyphrases
- prostate cancer
- locally advanced
- end stage renal disease
- newly diagnosed
- ejection fraction
- induced apoptosis
- chronic kidney disease
- cell therapy
- cell cycle arrest
- radical prostatectomy
- squamous cell carcinoma
- rectal cancer
- oxidative stress
- cell proliferation
- patient reported outcomes
- cell death
- radiation therapy
- combination therapy
- replacement therapy